Transfusion interventions in critical bleeding requiring massive transfusion: a systematic review

Area of Science:

• Transfusion Medicine
• Critical Care Medicine
• Evidence-Based Medicine

Background:

• Critical bleeding (CB) necessitating massive transfusion (MT) is linked to high mortality and morbidity.
• Previous Australian National Blood Authority (NBA) guidelines (2011) for CB and MT had limited evidence, yielding only two recommendations.
• Substantial evidence gaps remain in managing critical bleeding and massive transfusion protocols.

Purpose of the Study:

• To update existing patient blood management guidelines for critical bleeding and massive transfusion.
• To systematically review the latest evidence on transfusion interventions for critical bleeding.
• To identify remaining evidence gaps requiring further research.

Main Methods:

• A comprehensive systematic review and meta-analysis was conducted.
• Searched multiple databases (MEDLINE, Cochrane Library, EMBASE, etc.) for randomized controlled trials (RCTs) and systematic reviews (SRs) up to July 2014.
• Evidence was categorized based on transfusion interventions: RBC dose/timing/ratio, RBC transfusion effects, component therapy effects (FFP, platelets, cryoprecipitate, etc.), and recombinant activated factor VII (rFVIIa).

Main Results:

• Nineteen studies were identified, including 6 RCTs and 13 SRs.
• Limited new high-quality evidence was found since the 2011 guidelines.
• Significant evidence gaps persist, especially concerning the impact of component therapy ratios on patient outcomes.

Conclusions:

• The current evidence base for critical bleeding and massive transfusion management remains insufficient.
• There is a critical need for well-designed clinical trials to address the identified evidence gaps.
• Further research is required to optimize transfusion strategies and improve patient outcomes in critical bleeding scenarios.